GlassScriptPhysician profile
Elsa G Garza
NPI 1457581373
$12,789.73
in general payments reported to CMS, 2019-2025
28 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,378 · 2022: $1,486 · 2023: $7,521 · 2024: $1,007 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,235 · Food and Beverage: $2,414 · Travel and Lodging: $1,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,235.00 |
| Food and Beverage | $2,413.97 |
| Travel and Lodging | $1,277.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Health Care Systems INC. | $4,770.36 | 2023-2024 | Opsumit, Uptravi, Veletri |
| Actelion Pharmaceuticals US, INC. | $2,247.49 | 2021-2024 | Uptravi, Opsumit |
| United Therapeutics Corporation | $1,779.83 | 2021-2024 | Tyvaso |
| Glaxosmithkline, LLC. | $1,030.34 | 2021-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $773.60 | 2021-2025 | Airsupra, Tezspire, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $366.33 | 2021-2025 | |
| Harmony Biosciences LLC | $295.43 | 2021-2023 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.30 | 2021-2023 | Spiriva Respimat, Stiolto Respimat |
| Pfizer INC. | $156.73 | 2022-2025 | |
| Mylan Specialty L.P. | $146.36 | 2021-2023 | Yupelri |
| Jazz Pharmaceuticals INC. | $139.75 | 2021-2023 | |
| Pulmonx Corporation | $139.57 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Grifols USA, LLC | $116.50 | 2021-2023 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $81.86 | 2021-2023 | Glassia |
| Janssen Pharmaceuticals, INC | $68.61 | 2023-2024 | Opsumit, Uptravi |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $60.36 | 2022-2023 | |
| Viatris Specialty LLC | $58.82 | 2025 | Yupelri |
| Advanced Respiratory, INC | $38.99 | 2021 | |
| Vapotherm INC | $37.05 | 2022 | |
| Eisai INC. | $32.46 | 2021-2022 | |
| Genzyme Corporation | $31.52 | 2023 | |
| Baxter Healthcare | $30.43 | 2022 | |
| Philips North America LLC | $28.92 | 2023-2024 | (Ak6) Vest Therapy |
| Axsome Therapeutics, INC. | $26.17 | 2023 | Sunosi |
| Paratek Pharmaceuticals, INC. | $23.09 | 2023 | Nuzyra |
| Electromed, INC. | $21.93 | 2022 | |
| Merck Sharp & Dohme LLC | $18.48 | 2024 | Zerbaxa, Recarbrio |
| Inogen, INC. | $17.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elsa Garza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.